By Nadav Liam Modlin, PhD<\/p>\n
For many veterans, returning home marks not resolution but the beginning of a quieter struggle. Despite decades of innovation<\/a> in trauma-focused therapies and medication, a substantial number continue to live with psychological injuries that existing treatments only partly address. Their trauma is not merely a cluster of symptoms; it is a disruption of identity<\/a>, moral coherence, and belonging. It reflects lived experience shaped by early adversity, military culture, and the often-isolating aftermath of service.<\/p>\n Investigational psychedelic treatments have gained attention<\/a> because they may offer a way for veterans to engage more fully with traumatic<\/a> memories while also exploring identity, value, and meaning – dimensions often beyond the reach of conventional care. Preparing for their potential approval by regulatory authorities, and, if regulatory approval is obtained, adoption<\/a> requires more than enthusiasm for new interventions. It calls for deliberate provider training, veteran education<\/a>, and system-level readiness so that, if approved, these treatments are delivered within ethically grounded and well-coordinated care structures.<\/p>\n Understanding the Complex Nature of Veteran Trauma<\/p>\n Trauma among veterans is shaped by context as much as by events. Many describe a cumulative process: early adversity or instability, the structure and intensity of military life, and the destabilizing transition back to civilian environments. Because trauma often becomes intertwined with identity, loyalty, and responsibility, help-seeking can feel risky or foreign. Veterans may minimize distress, rely on solitary coping, or assume that providers without military experience will not understand the moral or interpersonal dimensions of their injuries.<\/p>\n These factors may help explain why some standard treatments fall short. Beyond hyperarousal or fear<\/a>, many veterans describe emotional flatness, disconnection, or a sense of being suspended between worlds. Back home and yet feeling distant from relationships, purpose, or former versions of themselves.<\/p>\n Understanding this broader internal landscape is essential before considering how psychedelic treatments might contribute. For many veterans, the challenge is not only processing traumatic memories but reconstructing coherence, connection, and trust in a life that feels altered by prolonged exposure to violence and war.<\/p>\n The Therapeutic Potential and Complexity of Psychedelic-Induced States<\/p>\n Psychedelic treatments invite patients into biopsychological, at times transcendental, states marked by intensified emotion<\/a>, vivid somatic sensations, and shifts in self-perception. For some veterans, this may be the first opportunity to approach traumatic memories without shutting down or dissociating<\/a>. In clinical trials, MDMA-assisted psychotherapy<\/a> appears to reduce fear-based reactivity and strengthen the therapeutic alliance, enabling more direct engagement with trauma (Feduccia et al., 2019; Mitchell et al., 2023). Psilocybin may facilitate indirect trauma engagement and broader shifts in perspective (Modlin et al., 2025), potentially offering access to values or narratives long muted by psychological burden. Further clinical trials are necessary to evaluate the safety and efficacy of psychedelic treatments, including psilocybin, as a treatment for trauma-related conditions and PTSD<\/a>.<\/p>\n However, these same possibilities introduce complexity. Psychedelic states can involve temporary anxiety<\/a>, disorientation, or emotional vulnerability. Qualitative research highlights that such experiences can include moments of struggle before resolution. Veterans may encounter difficult memories, intense emotions , or physical sensations such as nausea or tension. These reactions are typically short-lived under careful medical supervision, but they underscore the need for providers trained to support patients through the full arc of the experience.<\/p>\n Effective care requires a system capable of recognizing when emotional activation remains productive and when it risks destabilization. The potential of psychedelic treatments, if approved, rest not only in the compounds themselves but in the coordinated readiness of providers, patients, and the structures that support them.<\/p>\n Equipping Providers With Specialized Competencies<\/p>\n Providers working with veterans already bring substantial expertise: evidence-based trauma-informed practice, risk mitigation, and cultural competence, among other skills. Psychedelic treatment research builds on this foundation but introduces a distinct biopsychological landscape that requires additional preparation. The aim is to help investigators and healthcare providers work alongside and in service of the altered state itself within clinical trial settings, supporting participants as they navigate symbolic material, emotional depth, and shifts in self-perception without over-directing or constraining the process.<\/p>\n Training in clinical trials emphasizes moment-to-moment attunement, including noticing subtle affective shifts, calibrating pacing, allowing meaningful silence, and offering grounded presence during periods of intensity. Such training can deepen investigators\u2019 understanding of the phenomenology of psychedelic states while clarifying the distinctions between psychedelic trial procedures and traditional treatment paradigms, thereby informing more competent and responsive participant support. If psychedelic compounds were to receive regulatory approval as treatments in the future, this training foundation could help inform the development of appropriate, role-specific training frameworks to support safe and effective clinical implementation. <\/p>\n Because many veterans carry histories of moral injury<\/a>, discrimination<\/a>, or institutional betrayal, providers and care teams training must also account for cultural and interpersonal dynamics. Expanded states can heighten vulnerability, making transparency, collaboration<\/a>, and empowerment essential to ensuring that the treatment process remains psychologically safe and productive.<\/p>\n Preparing Veterans Through Clear and Culturally Attuned Education<\/p>\n Provider readiness alone is insufficient. Veterans benefit from education that prepares them for the experiential terrain of psychedelic treatment \u2014how altered states unfold, what they can facilitate, potential adverse events and how the treatment process differs from conventional options. Understanding distinctions between compounds (e.g., MDMA\u2019s interpersonal and empathogenic qualities versus psilocybin\u2019s introspective and perceptual shifts) helps set grounded expectations.<\/p>\n Education also supports veterans in anticipating emotional and somatic experiences, including shifts in mood, changes in body awareness, or unexpected internal sensations. Clear orientation helps normalize these responses and supports engagement with the experience with curiosity and openness<\/a> whilst post-administration follow-up sessions extend treatment education allowing veterans to contextualize their experience in relation to daily functioning.<\/p>\n A Coordinated Path Forward<\/p>\n Psychedelic treatments are currently being evaluated in clinical trials and hold promise for veterans whose psychological injuries have not fully responded to traditional approaches. Realizing this promise requires alignment across provider training, veteran education, and system-level design. Each component reinforces the others: providers need specialized competencies; veterans need clear guidance; and care systems must support continuity, safety, and equitable access.<\/p>\n If approached with care and consideration, psychedelic treatment can represent a meaningful evolution in trauma care – one that honors the depth and complexity of veterans\u2019 experiences and expands the tools available to support healing. The task ahead is not simply adopting new medications if and when regulatory approval is obtained but building the knowledge, collaboration, and structures necessary to deliver them wisely and ethically.<\/p>\n Nadav Liam Modlin, PhD, is Director of Clinical Care Research & Training for PTSD at Compass Pathways, where he leads the development of trauma-informed clinical care models for use in clinical trials, training for healthcare professionals involved in the conduct of clinical trials, and research to improve safety and quality in psilocybin treatment for post-traumatic stress<\/a> and related conditions. In this role, he integrates clinical expertise with applied research to shape care standards in psychedelic clinical trials. Previously, he served as a research therapist, clinical investigator, and lecturer at the Institute of Psychiatry<\/a>, Psychology & Neuroscience<\/a> (IoPPN), King\u2019s College London, where his work focused on trauma, psychopharmacology<\/a>, qualitative research into patient experience, and training providers in novel therapeutic approaches. Dr. Modlin also partners with Sunstone Therapies as a Therapist Training and Supervision Consultant, maintains a psychotherapeutic practice and has worked in NHS mental health services.<\/p>\n","protected":false},"excerpt":{"rendered":"By Nadav Liam Modlin, PhD For many veterans, returning home marks not resolution but the beginning of a…\n","protected":false},"author":2,"featured_media":418644,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[59,57,58,50,56,54,55],"class_list":{"0":"post-418643","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-united-kingdom","8":"tag-gb","9":"tag-great-britain","10":"tag-greatbritain","11":"tag-news","12":"tag-uk","13":"tag-united-kingdom","14":"tag-unitedkingdom"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/418643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=418643"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/418643\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/418644"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=418643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=418643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=418643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}